The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France (EQOL Study)
Sponsor: Medtronic Diabetes
This observational or N/A phase trial investigates Type 1 Diabetes and is currently completed. Medtronic Diabetes leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
-
Jul 2024 — Aug 2024 [monthly]
Completed
-
Dec 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting
▶ Show 9 earlier versions
-
Nov 2021 — Sep 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
May 2021 — Jun 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting
-
Apr 2020 — May 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Diabetes
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Besançon, France , Bobigny, France , Bordeaux, France , Boulogne-sur-Mer, France , Brest, France , Bron, France , Caen, France , Corbeil-Essonnes, France , Dijon, France and 19 more locations